Your Roivant shares will come from an ordinary broker with US market access, because the common shares of this Bermuda-incorporated, London-headquartered drug developer trade on the Nasdaq Global Select Market as ROIV, with no depositary receipt in between. What sets the stock apart is its structure: Roivant runs each drug through a subsidiary it calls a Vant, one of which, Immunovant, is listed in its own right, and in August 2026 the FDA approved LISRAYA, the drug that now gives the group product sales again. Below: the business, the order itself, and what the filings say can move the price.
What Does Roivant Do?
The annual report opens with a one-line mission: "Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter." The method follows straight after: "We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies."
The company was founded on 7 April 2014 as a Bermuda exempted company and went public in 2021 through a business combination with Montes Archimedes Acquisition Corp., a special purpose acquisition company. Its principal executive offices are in London; the 10-K also lists subsidiary addresses in New York and Basel.
A Vant is a small company with its own management team and its own equity incentives, built around one drug or one technology. Roivant in-licenses a compound, places it in a Vant and funds it, while keeping capital allocation decisions at the parent. Three Vants carry the current pipeline:
Priovant develops brepocitinib, an oral small molecule that inhibits JAK1 and TYK2, licensed from Pfizer. The FDA approved it in August 2026 as LISRAYA for adults with dermatomyositis, a chronic immune disease of the skin and muscles. In October 2026 the company reported that both Phase 3 trials in non-infectious uveitis, CLARITY-1 and CLARITY-2, met their primary and all key secondary endpoints. Trials in cutaneous sarcoidosis and lichen planopilaris are under way.
Immunovant develops IMVT-1402, a fully human antibody that targets FcRn, a receptor that recycles IgG antibodies, under a licence from HanAll Biopharma. It runs potentially registrational trials in Graves' disease, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, plus a programme in difficult-to-treat rheumatoid arthritis. An older antibody, batoclimab, was dropped in April 2026 after two Phase 3 studies in thyroid eye disease missed their primary endpoints.
Pulmovant develops mosliciguat, an inhaled sGC activator licensed from Bayer, for pulmonary hypertension associated with interstitial lung disease. After positive Phase 2 results in September 2026, the Phase 3 PHrontier study has begun enrolling.
Beyond those three, Genevant holds lipid nanoparticle (LNP) delivery technology, and Roivant keeps stakes in Datavant, Proxima and PsiThera. It has also sold whole Vants: Telavant to Roche in December 2023 and Dermavant to Organon in October 2024, keeping a right to future milestones and royalties from the latter. The 10-K counts 8 FDA approvals and 14 large registrational Phase 3 studies since 2014, 12 of them positive, including Vants later transferred to Sumitomo Pharma and Dermavant; that tally predates LISRAYA.
How Roivant Makes Money
Until August 2026, mostly by selling what it had built rather than by selling medicines. Revenue in the fiscal year ended 31 March 2026 fell about 72% from the year before, and the 10-K says it "was primarily driven by amounts earned in connection with license agreements at Genevant." Research and development spending rose about 24% in the same year, and the company still posted a net loss even after booking a gain from a patent settlement.
Money has come in through four channels:
| Source | What it is | Where it shows up |
|---|---|---|
| Product sales | LISRAYA, sold in the US since August 2026 | Product revenue, from the quarter ended 30 September 2026 |
| Licensing | Genevant's LNP licences to other drugmakers | License, milestone and other revenue |
| Patent litigation | Genevant and Arbutus claims over LNP technology | Gain on litigation settlement |
| Sales of Vants | Telavant to Roche, Dermavant to Organon | One-time gains and later milestones |
The first line is new. In the quarter ended 30 September 2026, product revenue made up about 88% of total revenue, and the 10-Q says it "relates entirely to the sale of LISRAYA in the U.S." The drug goes to specialty pharmacies, and over the six months to 30 September 2026 two of them accounted for 82% and 18% of gross product revenue. Priovant owes Pfizer a tiered royalty in the sub-teens on LISRAYA net sales.
The litigation line explains part of the cash pile. On 3 March 2026, Genevant and Arbutus settled all pending patent cases with Moderna worldwide. The first payment arrived in July 2026; a second depends on how Moderna's appeal under Section 1498 is resolved, and oral arguments took place on 5 November 2026. A separate case against Pfizer and BioNTech, filed in New Jersey in April 2023, received a claim construction ruling in September 2025 that Genevant considers generally favourable. The Moderna side of the dispute is in our Moderna stock guide.
One more layer matters: Roivant does not own all of each Vant. At 30 September 2026 its basic ownership was 71% of Priovant, 55% of Immunovant, 95% of Pulmovant and 83% of Genevant, plus 19% of Arbutus. Profits from LISRAYA, or from any future Immunovant drug, are shared with the other shareholders of those companies.
ROIV Stock at a Glance
| Feature | ROIV |
|---|---|
| Exchange | Nasdaq Global Select Market |
| Ticker | ROIV |
| Security | Common shares; the only class registered under Section 12(b) |
| Depositary receipt | None: the shares trade directly |
| Sector | Biopharmaceuticals, run through subsidiaries called Vants |
| Index membership | Held by MDY, the S&P MidCap 400 fund; not held by SPY (10 November 2026) |
| Incorporated | Bermuda, as an exempted company |
| Headquarters | London |
| Fiscal year | Ends 31 March |
| SEC reports | 10-K, 10-Q and 8-K, like a US company |
| Dividend | None ever declared or paid |
| SEC identifier | CIK 1635088 |
Price, market value and trading volume change by the second; for live figures, see the Roivant stock page on Bitbase.
How to Buy Roivant Stock
Because Roivant is a foreign company, some readers expect an ADR. There isn't one. The 10-K cover registers a single class, "Common Shares," on Nasdaq, so what you buy at a broker is the share itself. The steps:
1. Pick a broker that offers Nasdaq stocks. Outside the United States, that can be a local broker with US market access or an international one. Check which legal entity holds your account and who regulates it.
2. Open and verify the account. Non-US individuals are usually asked for IRS Form W-8BEN; the IRS tells foreign persons to "submit Form W-8 BEN when requested by the withholding agent or payer."
3. Fund it. Paying in a currency other than dollars adds a conversion step, so compare the exchange rate as well as the commission.
4. Search for ROIV. The result should read Roivant Sciences Ltd. common shares on Nasdaq. Do not confuse it with Immunovant or Arbutus, which have their own listings.
5. Choose the order type. A market order fills at the best available price; a limit order fills only at your price or better and may not fill at all. Biotech shares can jump on trial news, which is when a price limit helps.
6. Decide the size. Some brokers sell fractional shares, so you can invest a fixed sum; availability and voting treatment vary by firm.
7. Keep records. Confirmations and statements show your cost basis for tax.
Tax notes for investors abroad. Since Roivant pays no dividend, there is no dividend withholding to plan around for now; gains on a sale are taxed under the rules where you live. US holders face one extra question the 10-K raises itself, the passive foreign investment company test, covered under risks below.
Through funds. On 10 November 2026, Roivant Sciences Ltd. appeared in the daily holdings of State Street's MDY, an ETF tied to the S&P MidCap 400, where it is one of hundreds of positions.
What Moves ROIV Stock
The LISRAYA launch. Quarterly product revenue is now the cleanest read on whether physicians are prescribing the drug. Watch growth from quarter to quarter, the gap between gross and net sales, and how concentrated the specialty-pharmacy customers remain.
A second indication for brepocitinib. Priovant plans to file a supplemental application for non-infectious uveitis in the first half of 2027. In the CLARITY studies, 62% of patients on brepocitinib reached steroid-free quiescence at Week 48, against 20% on placebo, according to the 10-Q.
IMVT-1402 readouts. In difficult-to-treat rheumatoid arthritis, the 600 mg dose met its primary endpoint at Week 28 with a 92.5% ACR20 response, compared with 75.6% for placebo, while the 300 mg dose showed no difference; talks with the FDA on the path forward were planned for later in 2026. Immunovant has also said it is unlikely to take the drug further in Sjögren's disease beyond the current Phase 2 trial. The 10-K names approved FcRn blockers, including VYVGART, as potential competitors; that drug's maker is covered in our argenx stock guide.
Mosliciguat. In the PHocus study, the drug cut pulmonary vascular resistance by 56.3% against placebo at Week 16, which the company called the highest reduction ever reported in a randomised controlled PH trial. Phase 3 is now the test that counts.
Litigation money. The contingent Moderna payment is larger than the first one, so the Section 1498 ruling alone could change Roivant's cash position materially, and the Pfizer and BioNTech case is still pending.
Capital allocation. Roivant bought back about 24.0 million of its own shares in the year to 31 March 2026 and about 9.4 million in the following six months, and it also keeps an at-the-market programme through which it can sell new shares. How cash is split between buybacks, new in-licensing and Vant funding comes up on every earnings call.
Trial Data, Vant Dilution and Bermuda Law: Risks in ROIV
The 10-K's summary list is long. These entries bear most on the share:
Losses. "We will likely incur significant operating losses for the foreseeable future and may never achieve sustained profitability." One approved drug does not retire that sentence.
Licences. "Immunovant relies on the HanAll Agreement to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab." Losing significant rights under it, the 10-K adds, would hurt the development and sale of IMVT-1402.
The Vant model. Equity awards and fundraising at each Vant "may further dilute or subordinate our ownership and economic interests in the Vants." A ROIV share is a claim on a stake, not on the whole drug.
Data that can change. "Interim, preliminary or topline data from our clinical trials … may change as more patient data become available."
Policy. "Legislation targeting biotechnology companies with ties to certain foreign adversaries, including the BIOSECURE Act, could materially adversely affect our business," the 10-K warns; part of its manufacturing and trial work takes place in Asia.
Tax and jurisdiction. "U.S. holders of our common shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company." The asset test counts cash, and Roivant holds a great deal of cash and marketable securities. And as a Bermuda company, "the rights of our shareholders are governed by Bermuda law," while US court judgments can be harder to enforce against it.
Then come the plain risks of a single biotech stock: one trial result can move the price sharply either way, and no dividend cushions a fall.
How to Research ROIV Yourself
Roivant files with the SEC under CIK 1635088 on domestic forms: an annual 10-K (the latest filed on 20 May 2026), three 10-Qs a year and 8-Ks for news. In 2026 its quarterly results came out on 6 February, 20 May, 6 August and 9 November, each with an 8-K.
Four tables in the filings reward a closer look. The Vant ownership table, in Item 1 of the 10-K and in each 10-Q, shows basic and fully diluted stakes; compare the two columns over time to see how much dilution the Vants absorb. The milestone and royalty table lists what the Vants owe Pfizer, HanAll, Bayer and Arbutus as drugs advance, which reduces what Roivant keeps from future sales. The upcoming catalysts table gives expected timing by calendar year, which the 10-K says "may be subject to change." And product revenue in the 10-Q shows LISRAYA's quarterly sales and the customer concentration behind them.
Live quotes are on the stock page linked above, and the full list of US stock pages on Bitbase covers other listed drugmakers.
Roivant Stock FAQ
Can I buy Roivant stock with crypto?
Not directly. ROIV shares are bought through a brokerage account in US dollars, so crypto has to be sold for cash and moved to the broker first, a sale that may be taxable where you live. The two assets also give you different things: a share is a registered claim on a company, which is how a share differs from a crypto asset.
Does Roivant pay a dividend?
No. The 10-K says the company has "never declared or paid cash dividends" on its capital stock and does not expect to pay any in the foreseeable future. It has returned cash through share buybacks instead.
Is Roivant a UK company, and is ROIV an ADR?
Neither, strictly. Roivant is incorporated in Bermuda and has its principal executive offices in London. ROIV is not an ADR: the common shares themselves are listed on Nasdaq, and the company files 10-K and 10-Q reports rather than the 20-F used by many foreign issuers.
Is ROIV in the S&P 500?
No. On 10 November 2026, ROIV was not among the holdings of SPY, the S&P 500 fund, but was among those of MDY, which tracks the S&P MidCap 400. Index membership can change at any rebalance.
Does Roivant own Immunovant?
Mostly. At 30 September 2026, Roivant held 55% of Immunovant on a basic basis and 52% fully diluted. Immunovant is listed separately, so buying ROIV gives you an indirect stake in it alongside the other Vants.
Conclusion
Roivant is a holding company for drug bets as much as a drug company: each programme sits in a Vant it only partly owns, and its cash came largely from selling Vants and winning patent fights. LISRAYA gives the group a product revenue line again, yet most of the value still rides on IMVT-1402, mosliciguat and a second brepocitinib indication. Read the Vant ownership table and the latest 10-Q before deciding, and size the position for a stock that can move a lot on a single trial readout.
Related reading
Other Bitbase articles on this topic:
- How to Buy BeOne Medicines Stock (ONC): The Former BeiGene
- How to Buy Genmab Stock (GMAB): ADS Ratio and DARZALEX Royalties
- How to Buy IDEXX Stock (IDXX): Vet Diagnostics, No Dividend
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of November 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] Roivant Form 10-K for the fiscal year ended 31 March 2026 (SEC EDGAR) www.sec.gov
[2] Roivant 10-K, XBRL cover page (SEC EDGAR) www.sec.gov
[3] Roivant Form 10-Q for the quarter ended 30 September 2026 (SEC EDGAR) www.sec.gov
[4] Roivant Form 8-K, 9 November 2026 (SEC EDGAR) www.sec.gov
[5] Roivant Form 8-K on the CLARITY results, 21 October 2026 (SEC EDGAR) www.sec.gov
[6] State Street, MDY daily holdings (ssga.com) www.ssga.com
[7] IRS, About Form W-8 BEN www.irs.gov






